Affordable Access

Access to the full text

Molecular biomarkers in multiple sclerosis

Authors
  • Ziemssen, Tjalf1
  • Akgün, Katja1
  • Brück, Wolfgang2
  • 1 University Clinic Carl-Gustav Carus, Dresden University of Technology, Dresden, Germany , Dresden (Germany)
  • 2 University Medical Center, Göttingen, Germany , Göttingen (Germany)
Type
Published Article
Journal
Journal of Neuroinflammation
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Dec 23, 2019
Volume
16
Issue
1
Identifiers
DOI: 10.1186/s12974-019-1674-2
Source
Springer Nature
Keywords
License
Green

Abstract

Multiple sclerosis (MS) is an inflammatory-neurodegenerative disease of the central nervous system presenting with significant inter- and intraindividual heterogeneity. However, the application of clinical and imaging biomarkers is currently not able to allow individual characterization and prediction. Complementary, molecular biomarkers which are easily quantifiable come from the areas of immunology and neurobiology due to the causal pathomechanisms and can excellently complement other disease characteristics. Only a few molecular biomarkers have so far been routinely used in clinical practice as their validation and transfer take a long time. This review describes the characteristics that an ideal MS biomarker should have and the challenges of establishing new biomarkers. In addition, clinically relevant and promising biomarkers from the blood and cerebrospinal fluid are presented which are useful for MS diagnosis and prognosis as well as for the assessment of therapy response and side effects.

Report this publication

Statistics

Seen <100 times